The loudness dependence of the auditory evoked potential (LDAEP) as an in vivo biomarker of central serotonergic function in humans: rationale, evaluation and review of findings

The loudness dependence of the auditory evoked potential (LDAEP) has been proposed as a valid means of non‐invasively assessing in vivo central serotonin (5‐hydroxytryptamine, 5‐HT) function in humans. The specificity and sensitivity of the LDAEP to changes in 5‐HT neurotransmission have recently been explored directly in a number of pharmacological and genetic studies. Subsequently, this review was undertaken in an attempt to critically evaluate the potential role of the LDAEP as a marker of the central 5‐HT function.

[1]  Christoph Mulert,et al.  Association of 5‐HT1B receptor polymorphisms with the loudness dependence of auditory evoked potentials in a community‐based sample of healthy volunteers , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[2]  Pradeep J Nathan,et al.  Effects of selective and combined serotonin and dopamine depletion on the loudness dependence of the auditory evoked potential (LDAEP) in humans , 2008, Human psychopharmacology.

[3]  Pradeep J Nathan,et al.  An examination of acute changes in serotonergic neurotransmission using the loudness dependence measure of auditory cortex evoked activity: effects of citalopram, escitalopram and sertraline , 2008, Human psychopharmacology.

[4]  H. Buchner,et al.  Loudness dependence of evoked dipole source activity during acute serotonin challenge in females , 2008, Human psychopharmacology.

[5]  B. Müller,et al.  The intensity dependence of auditory ERP components in unmedicated patients with major depression and healthy controls. An analysis of group differences. , 2007, Journal of affective disorders.

[6]  D. Rujescu,et al.  Loudness dependence of auditory evoked potentials is not associated with polymorphisms or haplotypes in the serotonin transporter gene in a community-based sample of German healthy volunteers , 2007, Psychiatry Research.

[7]  Christoph Mulert,et al.  Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder. , 2007, The Journal of clinical psychiatry.

[8]  B. Brocke,et al.  An electrophysiological endophenotype of hypomanic and hyperthymic personality. , 2007, Journal of affective disorders.

[9]  Sumie Leung,et al.  High-dose glycine inhibits the loudness dependence of the auditory evoked potential (LDAEP) in healthy humans , 2007, Psychopharmacology.

[10]  H. Möller,et al.  [I-123] ADAM and SPECT in patients with borderline personality disorder and healthy control subjects. , 2007, Journal of psychiatry & neuroscience : JPN.

[11]  F. Artigas,et al.  Dopamine D2 receptor-mediated regulation of serotonin extracellular concentration in the dorsal raphe nucleus of freely moving rats. , 2006, Journal of neurochemistry.

[12]  G. Juckel,et al.  Is the loudness dependence of auditory evoked potentials modulated by the selective serotonin reuptake inhibitor citalopram in healthy subjects? , 2006, Human psychopharmacology.

[13]  David A Lewis,et al.  Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. , 2006, Archives of neurology.

[14]  M. Flores-Ramos,et al.  Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. , 2006, Journal of affective disorders.

[15]  G. Chastain.  Alcohol, Neurotransmitter Systems, and Behavior , 2006, The Journal of general psychology.

[16]  K. Phan,et al.  Dopamine receptor stimulation does not modulate the loudness dependence of the auditory evoked potential in humans , 2006, Psychopharmacology.

[17]  R. Devaki,et al.  The effect of lithium on the adrenoceptor-mediated second messenger system in the rat brain. , 2006, Journal of psychiatry & neuroscience : JPN.

[18]  E. Gouzoulis-Mayfrank,et al.  Intensity dependence of auditory evoked dipole source activity in polydrug ecstasy users: evidence from an 18 months longitudinal study , 2006, Journal of psychopharmacology.

[19]  R. Felix,et al.  Imaging of serotonin transporters and its blockade by citalopram in patients with major depression using a novel SPECT ligand [123I]-ADAM , 2006, Journal of Neural Transmission.

[20]  E. Esposito.  Serotonin-dopamine interaction as a focus of novel antidepressant drugs. , 2006, Current drug targets.

[21]  K. Lesch,et al.  Further Evidence for an Association of 5-HTTLPR with Intensity Dependence of Auditory-Evoked Potentials , 2006, Neuropsychopharmacology.

[22]  K. Phan,et al.  Direct evidence that acutely enhancing serotonin with the selective serotonin reuptake inhibitor citalopram modulates the loudness dependence of the auditory evoked potential (LDAEP) marker of central serotonin function , 2006, Human psychopharmacology.

[23]  Zsolt Szabo,et al.  Quantitative PET Studies of the Serotonin Transporter in MDMA Users and Controls Using [11C]McN5652 and [11C]DASB , 2005, Neuropsychopharmacology.

[24]  K. Chakrabarty,et al.  Glutamatergic Dysfunction in OCD , 2005, Neuropsychopharmacology.

[25]  A. Robles,et al.  N1/P2 component of auditory evoked potential reflect changes of the brain serotonin biosynthesis in rats , 2005, Nutritional neuroscience.

[26]  A. Meyer-Lindenberg,et al.  5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression , 2005, Nature Neuroscience.

[27]  A. Alavi,et al.  123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  G Sartory,et al.  The intensity dependence of auditory evoked ERP components predicts responsiveness to reboxetine treatment in major depression. , 2005, Pharmacopsychiatry.

[29]  Shih-Jen Tsai,et al.  Loudness dependence of the auditory evoked potential and response to antidepressants in Chinese patients with major depression. , 2005, Journal of psychiatry & neuroscience : JPN.

[30]  D. Javitt,et al.  Modulation of Striatal Dopamine Release by Glycine Transport Inhibitors , 2005, Neuropsychopharmacology.

[31]  L. Oreland,et al.  Role of the serotonin transporter gene and family function in adolescent alcohol consumption. , 2005, Alcoholism, clinical and experimental research.

[32]  M. Millan.  N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives , 2005, Psychopharmacology.

[33]  S. Faraone,et al.  Meta‐analysis of the association between two polymorphisms in the serotonin transporter gene and affective disorders , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[34]  Michael F Egan,et al.  A susceptibility gene for affective disorders and the response of the human amygdala. , 2005, Archives of general psychiatry.

[35]  P. Grasby,et al.  The effects of acute tyrosine and phenylalanine depletion on spatial working memory and planning in healthy volunteers are predicted by changes in striatal dopamine levels , 2005, Psychopharmacology.

[36]  H. Westenberg,et al.  The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. , 2004, The Journal of clinical psychiatry.

[37]  C. Kirschbaum,et al.  Effects of the menstrual cycle on auditory event-related potentials , 2004, Hormones and Behavior.

[38]  H. Möller,et al.  Serotonin and Dopamine Transporter Availabilities Correlate with the Loudness Dependence of Auditory Evoked Potentials in Patients with Obsessive-Compulsive Disorder , 2004, Neuropsychopharmacology.

[39]  Y. Sari.  Serotonin1B receptors: from protein to physiological function and behavior , 2004, Neuroscience & Biobehavioral Reviews.

[40]  B. Müller,et al.  The intensity dependence of the auditory evoked N1 component as a predictor of reponse to Citalopram treatment in patients with major depression , 2004, Neuroscience Letters.

[41]  Ralph Buchert,et al.  A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters. , 2004, The American journal of psychiatry.

[42]  B. Harrison,et al.  Simultaneous depletion of tryptophan, tyrosine and phenylalanine as an experimental method to probe brain monoamine function in humans. , 2004, The international journal of neuropsychopharmacology.

[43]  R. O. Friedel.  Dopamine Dysfunction in Borderline Personality Disorder: A Hypothesis , 2004, Neuropsychopharmacology.

[44]  J. Coyle,et al.  The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia , 2004, Psychopharmacology.

[45]  H. Möller,et al.  Loudness Dependence of Primary Auditory-Cortex-Evoked Activity as Predictor of Therapeutic Outcome to Prophylactic Lithium Treatment in Affective Disorders - A Retrospective Study , 2004, Pharmacopsychiatry.

[46]  Alain Dagher,et al.  Decreasing Amphetamine-Induced Dopamine Release by Acute Phenylalanine/Tyrosine Depletion: A PET/[11C]Raclopride Study in Healthy Men , 2004, Neuropsychopharmacology.

[47]  A. Massey,et al.  Lack of effect of tryptophan depletion on the loudness dependency of auditory event related potentials in healthy volunteers , 2004, Biological Psychology.

[48]  D. Weinberger,et al.  Functional neuroimaging of genetic variation in serotonergic neurotransmission , 2003, Genes, brain, and behavior.

[49]  P. Cowen,et al.  Reduction of brain dopamine concentration with dietary tyrosine plus phenylalanine depletion: an [11C]raclopride PET study. , 2003, The American journal of psychiatry.

[50]  M. Colado,et al.  The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) , 2003, Pharmacological Reviews.

[51]  E. Gouzoulis-Mayfrank,et al.  Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[52]  G. C. Wagner,et al.  Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. , 2003, Journal of pharmacological sciences.

[53]  S Debener,et al.  Allelic variation in serotonin transporter function associated with the intensity dependence of the auditory evoked potential , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[54]  Daniel Senkowski,et al.  Allelic Variants of the Functional Promoter Polymorphism of the Human Serotonin Transporter Gene is Associated with Auditory Cortical Stimulus Processing , 2003, Neuropsychopharmacology.

[55]  K. Gadde,et al.  Serotonin-Related Gene Polymorphisms and Central Nervous System Serotonin Function* , 2003, Neuropsychopharmacology.

[56]  K. Lesch,et al.  Toward a molecular architecture of personality , 2003, Behavioural Brain Research.

[57]  D. Senkowski,et al.  Evidence for disturbed cortical signal processing and altered serotonergic neurotransmission in generalized anxiety disorder , 2003, Biological Psychiatry.

[58]  Dan J Stein.  Obsessive-compulsive disorder , 2002, The Lancet.

[59]  M. Egan,et al.  Serotonin Transporter Genetic Variation and the Response of the Human Amygdala , 2002, Science.

[60]  Jun Yu Li,et al.  Initial conditions of serotonin transporter kinetics and genotype: influence on ssri treatment trial outcome , 2002, Biological Psychiatry.

[61]  T. Blackburn,et al.  The medical benefit of 5-HT research , 2002, Pharmacology Biochemistry and Behavior.

[62]  André Beauducel,et al.  Is auditory evoked potential augmenting/reducing affected by acute tryptophan depletion? , 2002, Biological Psychology.

[63]  T. Baldeweg,et al.  Electrophysiological evidence of serotonergic impairment in long-term MDMA ("ecstasy") users. , 2001, The American journal of psychiatry.

[64]  C. Cusin,et al.  Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity , 2001, Molecular Psychiatry.

[65]  W Zieglgänsberger,et al.  Glutamate receptors form hot spots on apical dendrites of neocortical pyramidal neurons. , 2001, Journal of neurophysiology.

[66]  G. Mengod,et al.  Control of serotonergic neurons in rat brain by dopaminergic receptors outside the dorsal raphe nucleus , 2001, Journal of neurochemistry.

[67]  R. Ebstein,et al.  Personality and polymorphisms of genes involved in aminergic neurotransmission. , 2000, European journal of pharmacology.

[68]  Camellia P. Clark,et al.  Clinical and Physiological Consequences of Rapid Tryptophan Depletion , 2000, Neuropsychopharmacology.

[69]  M Briley,et al.  The possible role of 5-HT(1B/D) receptors in psychiatric disorders and their potential as a target for therapy. , 2000, European journal of pharmacology.

[70]  J. Rodgers,et al.  Cognitive performance amongst recreational users of "ecstasy , 2000, Psychopharmacology.

[71]  Jörg Daumann,et al.  High Intensity Dependence of Auditory Evoked Dipole Source Activity Indicates Decreased Serotonergic Activity in Abstinent Ecstasy (MDMA) Users , 2000, Neuropsychopharmacology.

[72]  U. McCann,et al.  (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Clinical Studies , 2000, Neuropsychobiology.

[73]  G. Juckel,et al.  Loudness dependence of auditory evoked potentials in obsessive–compulsive disorder: a pilot study , 2000, Psychiatry Research.

[74]  Z. Szabo,et al.  Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). , 2000, Toxicology letters.

[75]  G. Stotz,et al.  The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression , 2000, Psychopharmacology.

[76]  E. Smeraldi,et al.  Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. , 2000, Journal of clinical psychopharmacology.

[77]  B. Carroll,et al.  Serotonin transporter gene polymorphism and antidepressant response , 2000, Neuroreport.

[78]  J. Zohar,et al.  Obsessive Compulsive Disorder: Serotonin and Beyond , 2000, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[79]  André Beauducel,et al.  Sensation Seeking and Affective Disorders: Characteristics in the Intensity Dependence of Acoustic Evoked Potentials , 2000, Neuropsychobiology.

[80]  Valéria Csépe,et al.  Auditory Evoked Potentials Reflect Serotonergic Neuronal Activity—A Study in Behaving Cats Administered Drugs Acting on 5-HT1A Autoreceptors in the Dorsal Raphe Nucleus , 1999, Neuropsychopharmacology.

[81]  J. Gorman,et al.  The noradrenergic system in pathological anxiety: a focus on panic with relevance to generalized anxiety and phobias , 1999, Biological Psychiatry.

[82]  Thomas Dierks,et al.  Intensity dependence of auditory evoked potentials (AEPs) as biological marker for cerebral serotonin levels: effects of tryptophan depletion in healthy subjects , 1999, Psychopharmacology.

[83]  G. Ricaurte,et al.  Altered Serotonin Innervation Patterns in the Forebrain of Monkeys Treated with (±)3,4-Methylenedioxymethamphetamine Seven Years Previously: Factors Influencing Abnormal Recovery , 1999, The Journal of Neuroscience.

[84]  B. Brocke,et al.  Biopsychological bases and behavioral correlates of sensation seeking: contributions to a multilevel validation , 1999 .

[85]  J. Davidson,et al.  Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives , 1998, Biological Psychiatry.

[86]  C. Parsons,et al.  Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. , 1998, Pharmacological reviews.

[87]  Z. Szabo,et al.  Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings , 1998, The Lancet.

[88]  M. Leboyer,et al.  Serotonin transporter gene polymorphisms in patients with unipolar or bipolar depression , 1998, Neuroscience Letters.

[89]  M. Morgan.  Recreational Use of “Ecstasy” (MDMA) Is Associated with Elevated Impulsivity , 1998, Neuropsychopharmacology.

[90]  I. Lucki,et al.  The spectrum of behaviors influenced by serotonin , 1998, Biological Psychiatry.

[91]  H. Baumgarten,et al.  Role of serotonin in obsessive-compulsive disorder , 1998, British Journal of Psychiatry.

[92]  L. Kelland.  Signal transduction pathways. , 1998, IDrugs : the investigational drugs journal.

[93]  R. Depue,et al.  Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions. , 1998, Cerebral cortex.

[94]  D. Easton,et al.  Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders. , 1998, American journal of medical genetics.

[95]  A. Parrott,et al.  Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance , 1998, Psychopharmacology.

[96]  G. Gerra,et al.  Serotonergic function after (±)3,4‐methylene-dioxymethamphetarnine (‘Ecstasy’) in humans , 1998, International clinical psychopharmacology.

[97]  A. Young,et al.  Rapid depletion of plasma tryptophan: a review of studies and experimental methodology , 1997, Journal of psychopharmacology.

[98]  G. Karmos,et al.  Auditory-evoked potentials as indicator of brain serotonergic activity first evidence in behaving cats , 1997, Biological Psychiatry.

[99]  C. Montigny,et al.  Differences between males and females in rates of serotonin synthesis in human brain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[100]  C. Montigny,et al.  The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments , 1997, Brain Research Reviews.

[101]  K. Lesch,et al.  Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region , 1996, Science.

[102]  H. Fibiger,et al.  Glutamate receptor agonists decrease extracellular dopamine in the rat nucleus accumbens in vivo , 1996, Synapse.

[103]  Georg Juckel,et al.  Serotonergic ethanol effects and auditory evoked dipole activity in alcoholic and healthy subjects , 1996, Psychiatry Research.

[104]  G. Goodwin,et al.  Polymorphism in serotonin transporter gene associated with susceptibility to major depression , 1996, The Lancet.

[105]  J. Krystal,et al.  Glycine Site Agonists of the NMDA Receptor: A Review , 1995 .

[106]  Charles Freer,et al.  Functional Neuroimaging , 1995 .

[107]  U. Hegerl,et al.  Sensory cortical processing and the biological basis of personality , 1995, Biological Psychiatry.

[108]  G. Juckel,et al.  The tridimensional personality questionnaire and the intensity dependence of auditory evoked dipole source activity , 1995, Biological Psychiatry.

[109]  U. Hegerl,et al.  Dipole Source Analysis , 1994, Pharmacopsychiatry.

[110]  E. A. Fedorov,et al.  ESR and magnetic susceptibility of Nd:YAG crystals , 1993 .

[111]  Georg Juckel,et al.  Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: A new hypothesis , 1993, Biological Psychiatry.

[112]  B. Müller-Oerlinghausen,et al.  Intensity dependence of auditory evoked potentials and clinical response to prophylactic lithium medication: A replication study , 1992, Psychiatry Research.

[113]  M. Spoont.  Modulatory role of serotonin in neural information processing: implications for human psychopathology. , 1992, Psychological bulletin.

[114]  K. Yoshimoto,et al.  Ethanol enhances the release of dopamine and serotonin in the nucleus accumbens of HAD and LAD lines of rats. , 1992, Alcoholism, clinical and experimental research.

[115]  G. Ricaurte,et al.  Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. , 1992, The Journal of pharmacology and experimental therapeutics.

[116]  M. Carrillo-de-la-Peña.  ERP augmenting/reducing and sensation seeking: a critical review. , 1992, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[117]  S. Camposano,et al.  Effects of stimulation intensity, gender and handedness upon auditory evoked potentials. , 1992, Arquivos de neuro-psiquiatria.

[118]  J. Hsiao,et al.  The Mechanisms of Action of Lithium: II. Effects on Adenylate Cyclase Activity and β-Adrenergic Receptor Binding in Normal Subjects , 1991 .

[119]  D. Murphy,et al.  Peripheral Indices of Central Serotonin Function in Humans , 1990, Annals of the New York Academy of Sciences.

[120]  Ting-kai Li,et al.  Serotonin, dopamine and GABA involvement in alcohol drinking of selectively bred rats. , 1990, Alcohol.

[121]  W. Herrmann,et al.  Effects of lithium on auditory evoked potentials in healthy subjects , 1990, Biological Psychiatry.

[122]  Michael J. Minzenberg,et al.  Extracellular serotonin and 5-hydroxyindoleacetic acid in hypothalamus of the unanesthetized rat measured by in vivo dialysis coupled to high-performance liquid chromatography with electrochemical detection: dialysate serotonin reflects neuronal release , 1989, Brain Research.

[123]  A. Pletscher.  Platelets as models: Use and limitations , 1988, Experientia.

[124]  J. Gruzelier,et al.  The augmenting/reducing phenomenon in the auditory evoked potential , 1984, Biological Psychology.

[125]  P. Jenner.  The Biochemical Basis of Neuropharmacology. 4th ed , 1984 .

[126]  M. Jenike.  Obsessive compulsive disorder. , 1983, Comprehensive psychiatry.

[127]  J. Glowinski,et al.  Regulation of serotonin synthesis. , 1974, Life sciences.

[128]  Irwin J. Kopin,et al.  The Biochemical Basis of Neuropharmacology , 1971, The Yale Journal of Biology and Medicine.

[129]  M. Buchsbaum,et al.  Individual differences in stimulus intensity response. , 1971, Psychophysiology.

[130]  M. Buchsbaum,et al.  Stimulus Intensity Control and the Cortical Evoked Response , 1968, Psychosomatic medicine.

[131]  John F. G. Atack,et al.  Serotonin Transporter , 2021, Encyclopedia of Evolutionary Psychological Science.

[132]  C. Parsons,et al.  Modulation of NMDA receptors by glycine — introduction to some basic aspects and recent developments , 2005, Amino Acids.

[133]  R. Pihl,et al.  Tryptophan depletion causes a rapid lowering of mood in normal males , 2004, Psychopharmacology.

[134]  Helmut Buchner,et al.  Enhanced intensity dependence as a marker of low serotonergic neurotransmission in borderline personality disorder. , 2003, Journal of psychiatric research.

[135]  Floyd E. Bloom,et al.  The biochemical basis of neuropharmacology, 8th ed. , 2003 .

[136]  P. Thompson,et al.  The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: persistence and new cases over 1 year of follow-up. , 2001, The Journal of clinical psychiatry.

[137]  J. Davidson,et al.  Pharmacotherapy of generalized anxiety disorder. , 2001, The Journal of clinical psychiatry.

[138]  K. Ressler,et al.  Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders , 2000, Depression and anxiety.

[139]  M. Morgan.  Memory deficits associated with recreational use of “ecstasy” (MDMA) , 1999, Psychopharmacology.

[140]  Philip J. Cowen,et al.  Effect of a tyrosine-free amino acid mixture on regional brain catecholamine synthesis and release , 1999, Psychopharmacology.

[141]  W. Burke,et al.  Amplitude/intensity functions of auditory event-related potentials predict responsiveness to bupropion in major depressive disorder. , 1995, Psychopharmacology bulletin.

[142]  J. P. Kline,et al.  Event-related potential amplitude/intensity slopes predict response to antidepressants. , 1994, Neuropsychobiology.

[143]  M. Pangalos,et al.  Neurotransmitter receptors of rat cortical pyramidal neurones: implications for in vivo imaging and therapy. , 1993, Journal of reproduction and fertility. Supplement.

[144]  M C Boadle-Biber,et al.  Regulation of serotonin synthesis. , 1993, Progress in biophysics and molecular biology.

[145]  G. Tyce,et al.  Origin and Metabolism of Serotonin , 1990, Journal of cardiovascular pharmacology.

[146]  K. Zilles,et al.  Distribution of cholinergic receptors in the rat and human neocortex. , 1989, EXS.

[147]  D. Charney,et al.  Lithium treatment and serotoninergic function. Neuroendocrine and behavioral responses to intravenous tryptophan in affective disorder. , 1989, Archives of general psychiatry.

[148]  C. Barthélémy,et al.  Frontal auditory-evoked potential augmenting-reducing and urinary homovanillic acid. , 1986, Neuropsychobiology.

[149]  M J Campbell,et al.  The monoaminergic innervation of primate neocortex. , 1986, Human neurobiology.

[150]  L. Knorring,et al.  Biochemistry of the augmenting-reducing response in visual evoked potentials. , 1981, Neuropsychobiology.

[151]  John F. G. Atack,et al.  SIGNAL TRANSDUCTION PATHWAYS , 2022 .